Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 385

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 385
---
 Remaining Amortization Period (Years)Commercial milestones$59,000 $(7,092)$51,908 12.6Developed technology226,620 (29,248)197,372 10.7Assembled workforce970 (431)539 1.7Total intangible assets$286,590 $(36,771)$249,819 11.1Amortization expense was $6.0 million and $5.5 million for the three months ended March 31, 2025 and 2024, respectively. Amortization expense was included in cost of sales in the accompanying unaudited condensed consolidated statements of operations. The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of March 31, 2025 (in thousands): Amount2025 (remaining nine months)17,924 202623,791 202723,575 202823,575 202923,575 Thereafter131,405  $243,845 

13

Accrued ExpensesAccrued expenses consist of the following (in thousands): March 31,2025December 31,2024Accrued sales deductions$43,132 $37,361 Accrued compensation and related benefits16,599 32,248 Accrued professional service fees13,969 12,545 Accrued contract manufacturing and non-clinical costs8,304 7,555 Accrued royalties payable10,088 9,361 Accrued clinical trials9,843 7,148 Accrued interest5,271 2,108 Accrued loss on firm purchase commitments2,088 1,898 Operating lease liabilities, current1,644 1,709 Accrued milestone payment5,000 — Total accrued expenses and other current liabilities$115,938 $111,933 Other liabilitiesOther liabilities consist of the following (in thousands): March 31,2025December 31,2024Noncurrent accrued sales deductions and other$9,952 $— Noncurrent accrued loss on firm purchase commitments3,948 2,509 Total other liabilities$13,900 $2,509 

6. Asset Acquisitions

License Agreement with Enthorin Therapeutics, LLCIn October 2024, the Company entered into a license agreement with Enthorin Therapeutics, LLC